Teva Pharmaceutical Industries Ltd (TEVA)
14.11
-0.32
(-2.22%)
USD |
NYSE |
Mar 28, 16:00
14.10
0.00 (0.00%)
After-Hours: 20:00
Teva Pharmaceutical Industries Cash from Financing (TTM): -1.913B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -1.913B |
September 30, 2023 | -2.048B |
June 30, 2023 | -1.912B |
March 31, 2023 | -2.195B |
December 31, 2022 | -1.487B |
September 30, 2022 | -1.277B |
June 30, 2022 | -2.014B |
March 31, 2022 | -1.677B |
December 31, 2021 | -2.172B |
September 30, 2021 | -1.796B |
June 30, 2021 | -1.676B |
March 31, 2021 | -1.678B |
December 31, 2020 | -1.885B |
September 30, 2020 | -2.001B |
June 30, 2020 | -2.405B |
March 31, 2020 | -2.437B |
December 31, 2019 | -1.926B |
September 30, 2019 | -2.184B |
June 30, 2019 | -1.428B |
March 31, 2019 | -1.449B |
December 31, 2018 | -3.351B |
September 30, 2018 | -5.358B |
June 30, 2018 | -5.478B |
March 31, 2018 | -6.073B |
December 31, 2017 | -5.75B |
Date | Value |
---|---|
September 30, 2017 | -3.945B |
June 30, 2017 | 22.25B |
March 31, 2017 | 23.18B |
December 31, 2016 | 25.22B |
September 30, 2016 | 30.63B |
June 30, 2016 | 4.171B |
March 31, 2016 | 4.979B |
December 31, 2015 | 4.805B |
September 30, 2015 | -503.00M |
June 30, 2015 | 258.00M |
March 31, 2015 | -1.648B |
December 31, 2014 | -2.375B |
September 30, 2014 | -2.401B |
June 30, 2014 | -2.328B |
March 31, 2014 | -2.257B |
December 31, 2013 | -3.883B |
September 30, 2013 | -2.998B |
June 30, 2013 | -3.312B |
March 31, 2013 | -3.325B |
December 31, 2012 | -1.678B |
September 30, 2012 | 2.148B |
June 30, 2012 | 3.416B |
March 31, 2012 | 3.493B |
December 31, 2011 | 3.336B |
September 30, 2011 | -1.329B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-2.437B
Minimum
Mar 2020
-1.277B
Maximum
Sep 2022
-1.878B
Average
-1.912B
Median
Cash from Financing (TTM) Benchmarks
Corcept Therapeutics Inc | -148.72M |
GSK PLC | -7.019B |
Sanofi SA | -- |
AstraZeneca PLC | -6.567B |
Novartis AG | -14.28B |